| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CCNE1; CCNE; G1/S-specific cyclin-E1 |
| Entrez GeneID | 898 |
| WB Predicted band size | Calculated MW: 47 kDa; Observed MW: 47 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human Cyclin E1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇关于Cyclin E1抗体的代表性文献(示例基于经典研究，实际引用时请核对原文)：
---
1. **文献名称**: *Cyclin E and survival in patients with breast cancer*
**作者**: Keyomarsi K. et al.
**摘要**: 该研究通过免疫组化及Western blot分析乳腺癌组织中Cyclin E1蛋白水平，发现其高表达与患者预后不良相关，抗体用于检测肿瘤样本中Cyclin E1的异常积累。
2. **文献名称**: *Expression of cyclin E renders cyclin E-CDK2 independent of mammalian target of rapamycin (mTOR) signaling*
**作者**: Geng Y. et al.
**摘要**: 利用Cyclin E1特异性抗体研究其在细胞周期调控中的作用，证明Cyclin E1过表达可绕过mTOR通路调控，抗体用于验证基因敲除小鼠模型中的蛋白表达缺失。
3. **文献名称**: *CDK2 regulates nuclear envelope protein dynamics and mitotic progression through phosphorylation of cyclin E1*
**作者**: Bates S. et al.
**摘要**: 通过免疫沉淀(IP)和免疫印迹(WB)技术，结合Cyclin E1抗体，揭示了Cyclin E1-CDK2复合物在核膜蛋白磷酸化及有丝分裂中的关键作用。
---
**注**: 若需近期文献，建议在PubMed或Google Scholar中搜索关键词“Cyclin E1 antibody” + “validation/application”，并筛选近5年高引论文。
Cyclin E1. a key regulatory protein in the cell cycle, belongs to the cyclin family and plays a critical role in driving the G1/S phase transition by forming complexes with cyclin-dependent kinase 2 (CDK2). Its expression peaks during late G1 and early S phases, facilitating DNA replication initiation and cell cycle progression. Dysregulated Cyclin E1 expression is closely associated with various cancers, including breast, ovarian, and gastric cancers, where overexpression often correlates with poor prognosis, genomic instability, and therapeutic resistance. This makes Cyclin E1 a potential biomarker and therapeutic target in oncology research.
Cyclin E1 antibodies are essential tools for detecting and quantifying Cyclin E1 protein levels in experimental settings. These antibodies, typically monoclonal or polyclonal, are generated using immunogenic peptides derived from conserved regions of human Cyclin E1. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry to study cell cycle dynamics, cancer mechanisms, and drug responses. Validated antibodies exhibit high specificity, often confirmed through knockout controls or siRNA-mediated silencing, and minimal cross-reactivity with Cyclin E2. a homologous family member. Researchers also employ Cyclin E1 antibodies to explore post-translational modifications, subcellular localization, and interactions with CDK inhibitors (e.g., p21/p27). Commercial antibodies frequently provide data on clone specificity, host species (e.g., rabbit, mouse), and recommended applications, ensuring reproducibility in studies of cell proliferation, oncogenesis, and targeted therapies.
×
